Abraxane

Adult Dosing .

Dosage forms:  INJ

Special Note

[formulation clarification]

Info: not interchangeable w/ non-albumin-bound paclitaxel formulations; do not substitute on a mg to mg basis

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing incl. toxicity-related dose adjustments

breast CA, refractory metastatic or relapsed

[260 mg/m^2/dose IV x1 on day 1 of 21-day cycle]

non-small cell lung CA, locally advanced or metastatic

[100 mg/m^2/dose IV x1 on days 1, 8, 15 of 21-day cycle]

Info: use w/ carboplatin

pancreatic CA, metastatic

[125 mg/m^2/dose IV x1 on days 1, 8, 15 of 28-day cycle]

Info: use w/ gemcitabine

renal dosing

[see below]

CrCl >30: no adjustment; CrCl <30: not defined

HD/PD: not defined

hepatic dosing

[breast CA, metastatic or relapsed]

AST <10x ULN and bilirubin 1.6-5x ULN: give 200 mg/m^2/dose for 1st 2 cycles, may incr. up to 260 mg/m^2/dose for subsequent cycles; AST >10x ULN or bilirubin >5x ULN: avoid use

[non-small cell lung CA, locally advanced or metastatic]

AST <10x ULN and bilirubin 1.6-5x ULN: give 80 mg/m^2/dose for 1st 2 cycles, may incr. to 100 mg/m^2/dose for subsequent cycles; AST >10x ULN or bilirubin >5x ULN: avoid use

[pancreatic CA, metastatic]

AST >10x ULN or bilirubin >1.5x ULN: avoid use

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.